SHAREHOLDER NOTICE: Brodsky & Smith, LLC Announces an Investigation of Stemline Pharmaceuticals, Inc. (NasdaqGS – STML)

BALA CYNWYD – May 8, 2020 /Access Wire/ – Law office of Brodsky & Smith, LLC announces that it is investigating potential claims against the Board of Directors of Stemline Therapeutics, Inc. (“Stemline” or the “Company”)(NasdaqGS – STML) for possible breaches of fiduciary duty and other violations of federal and state law in connection with proposed acquisition of the Company by the Menarini Group. Under the terms of the agreement, Stemline shareholders will receive only $12.50 consisting of an upfront payment of $11.50 in cash and a contingent value right appraised at $1.00 for each share of Stemline they own.

The investigation concerns whether the Stemline Board breached its fiduciary duties to shareholders by failing to conduct a fair process and whether Menarini is underpaying for the Company. For example, at least one analyst has set a target price for Stemline of $33.00 per share.

If you own shares of Stemline stock and wish to discuss the legal ramifications of the investigation, or have any questions, you may e-mail or call the law office of Brodsky & Smith, LLC who will, without obligation or cost to you, attempt to answer your questions. You may contact Jason L. Brodsky, Esquire, or Marc L. Ackerman, Esquire at Brodsky & Smith, LLC, Two Bala Plaza, Suite 510, Bala Cynwyd, PA 19004, or calling toll free 877-534-2590.

Brodsky & Smith, LLC is a litigation law firm with extensive expertise representing shareholders throughout the nation in securities and class action lawsuits. The attorneys at Brodsky & Smith have been appointed by numerous courts throughout the country to serve as lead counsel in class actions and have successfully recovered millions of dollars for our clients and shareholders. Attorney advertising. Prior results do not guarantee a similar outcome.